In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more. Read the full coverage here:

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema

OCS-01 eye drop for DME in second stage of phase 3 trial

Q&A: Susvimo delivers immediate durability after implantation in wet AMD

References:

Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Press Release

Press Release

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more. Read the full coverage here:

Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations

Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease

Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk

S100 protein levels predict abatacept response in juvenile idiopathic arthritis

Izokibep shows early promise in hidradenitis suppurativa

References:

Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0.

Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6.

Press Release

Press Release

Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473.

In this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more. Read the full coverage here:

Low education level raises risk for loss to follow-up in lung cancer screening program

Lung cancer screening judgement strongly influenced by clinicians

Occupational benzene exposure heightens lung cancer likelihood

Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF

Blood biomarker identifying benign lung nodules performs well across subgroups

References:

Ikeda S, et al. Ann Am Thorac Soc. 2024;doi:10.1513/AnnalsATS.202311-941OC.

Long KJ, et al. CHEST. 2023;doi:10.1016/j.chest.2023.06.037.

Mugutso E, et al. Ann Am Thorac Soc. 2023;doi:10.1513/AnnalsATS.202304-348RL.

Núñez ER, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202301-0155OC.

Wan W, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202306-0942OC.

In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here:

Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD

VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME

DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema

Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema

VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years

References:

Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.

Press Release

Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Read the full coverage here:

Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years

Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription

FDA approves biosimilar Pyzchiva for all approved Stelara indications

Tofacitinib effective for juvenile idiopathic arthritis through 4 years

Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes

References:

Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094.

Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277.

Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378.

Press Release

Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.

In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Read the full coverage here:

Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC

Lung cancer risks persist with e-cigarette use after quitting tobacco smoking

COPD, IPF end of life health care use differs from lung cancer

Tecentriq combination fails to improve survival in metastatic lung cancer

Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia

References:

Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston.

Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego.

Press Release

Suen AO, et al. Am J Respir Crit Care Med. 2024;doi:10.1154/ajrccm-conference.2024.209.1_MeetingAbstracts.A5040.

Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vabysmo prefilled syringe for retinal diseases

VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates

FDA approves Eylea biosimilar FYB203/Ahzantive

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ANI Pharmaceuticals to acquire Alimera Sciences

References:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

Press Release

Press Release

Press Release

Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more. Read the full coverage here:

Extensive psoriasis, IBD history predict difficult-to-treat psoriatic arthritis

Targeted psoriatic arthritis therapies demonstrate low risk for serious infection

VIDEO: Dermatologists, rheumatologists share care in psoriasis, psoriatic arthritis

Patients with arthritis at higher risk for poor nutrition regardless of function

FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older

References:

Bastard L, et al. RMD Open. 2024;doi:10.1136/rmdopen-2023-003865.

Bennett R, et al. Sci Rep. 2024;doi:10.1038/s41598-024-58370-7.

Husni ME. Update in the treatment of psoriatic arthritis. Presented at: Medical Dermatology Therapy Update III; May 29-31, 2024; Cleveland.

Press Release

Vassilakis KD, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae263.

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more. Read the full coverage here:

Lung cancer screening program identifies airways disease in previously undiagnosed COPD

Positive results in lung cancer show benefits of subcutaneous bispecifics

Adagrasib delays progression of pretreated KRAS-mutant lung cancer

Durvalumab extends survival in limited-stage small-cell lung cancer

Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer

References:

Bernstein E, et al. JCO Precis Oncol. 2024;doi:10.1200/po.23.00447.

Leighl NB, et al. Abstract LBA8505. Presented at: ASCO Annual Meeting; May 30–June 3, 2024; Chicago.

Ramalingam SS, et al. Abstract LBA4. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

Seigo MA, et al. Pulmonary comorbidities, respiratory symptoms, and spirometry in a real-world, urban lung cancer screening program. Presented at: American Thoracic Society International Conference; May 17-22, 2024; San Diego.

Spigel DR, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:

VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema

Merck to acquire EyeBio

VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME

Phase 2 study of potential DME oral therapy meets primary endpoints

FDA approves aflibercept biosimilars Yesafili, Opuviz

References:

Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.

Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.

Press Release

Press Release

Press Release